The new test can be used to see if potential vaccines work, to check what proportion of the population has already been infected, and for contact tracing, which is critical as Singapore eases up on circuit breaker measures.
At a virtual press conference on Friday , the medical school announced that it will be co-developing and manufacturing the kit, known as cPass, with biotech company GenScript Biotech Corporation and the Agency for Science, Technology and Research's Diagnostics Development Hub .The test can be carried out in most research or clinical labs, said Duke-NUS.
Prof Wang said:"The cPass developed by our team can be used for contact tracing, reservoir or intermediate animal tracking, assessment of herd immunity, longevity of protective immunity and efficacy of different vaccine candidates. It also developed the manufacturing protocol and quality controls to secure its provisional authorisation by the Health Sciences Authority.
Finally, GenScript was responsible for proof-of-concept research, product design, and development and optimisation, and will now play a central role in the commercialisation process using its global network and manufacturing capacity to launch cPass in Singapore and around the world.
Khairykj When is Malaysia going to try to create their own innovation without relying on outside sources
Accuracy rate?
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: malaymail - 🏆 1. / 86 Read more »